EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimised plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial

Matthew B O'Rourke, Andrzej S Januszewski, David R Sullivan, Imre Lengyel, Alan J Stewart, Swati Arya, Ronald C Ma, Sanjeev Galande, Anandwardhan A Hardikar, Mugdha V Joglekar, Anthony C Keech, Alicia J Jenkins und 1 weitere

PROTEOMICS – Clinical Applications · 2023

DOI: 10.1002/prca.202200106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, 2023. Verfasst von Matthew B O'Rourke und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bowel Cancer & Biomarker Lab, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Fenofibrate, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Robust, affordable plasma proteomic biomarker workflows are needed for large‐scale clinical studies. We evaluated aspects of sample preparation to allow liquid chromatography‐mass spectrometry (LC‐MS) analysis of more than 1500 samples from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial of adults with type 2 diabetes.

Methods

Using LC‐MS with data‐independent acquisition we evaluated four variables: plasma protein depletion, EDTA or citrated anti‐coagulant blood collection tubes, plasma lipid depletion strategies and plasma freeze–thaw cycles. Optimised methods were applied in a pilot study of FIELD participants.

Results

LC‐MS of undepleted plasma conducted over a 45 min gradient yielded 172 proteins after excluding immunoglobulin isoforms. Cibachrome‐blue‐based depletion yielded additional proteins but with cost and time expenses, while immunodepleting albumin and IgG provided few additional identifications. Only minor variations were associated with blood collection tube type, delipidation methods and freeze–thaw cycles. From 65 batches involving over 1500 injections, the median intra‐batch quantitative differences in the top 100 proteins of the plasma external standard were less than 2%. Fenofibrate altered seven plasma proteins. Conclusions and clinical relevance A robust plasma handling and LC‐MS proteomics workflow for abundant plasma proteins has been developed for large‐scale biomarker studies that balance proteomic depth with time and resource costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FenofibrateDiabetes Mellitus, Type 2AdultHumansChromatography, LiquidProteomicsPilot ProjectsTandem Mass SpectrometryBlood ProteinsBiomarkers

Stichwörter der Autor:innen

Biomarkerdiabetesfenofibratemass spectrometryplasmaproteomics

Substanzen

FenofibrateBlood ProteinsBiomarkers

Autor:innen und Institutionen

  • Bowel Cancer & Biomarker Lab, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Centre for Inflammation, Centenary Institute, Sydney, Australia.
  • School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, Australia.
  • NHMRC Clinical Trials Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Department of Chemical Pathology, Royal Prince Alfred Hospital, NSW Health Pathology, Australia.
  • Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Belfast, Belfast, UK.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

O'Rourke, M. B., Januszewski, A. S., Sullivan, D. R., Lengyel, I., Stewart, A. J., Arya, S., Ma, R. C., Galande, S., Hardikar, A. A., Joglekar, M. V., Keech, A. C., Jenkins, A. J., & Molloy, M. P. (2023). Optimised plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial. PROTEOMICS – Clinical Applications. https://doi.org/10.1002/prca.202200106

Vancouver

O'Rourke MB, Januszewski AS, Sullivan DR, Lengyel I, Stewart AJ, Arya S, et al. Optimised plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial. PROTEOMICS – Clinical Applications. 2023. doi:10.1002/prca.202200106

BibTeX
@article{ORourke2023,
  author = {O'Rourke, Matthew B and Januszewski, Andrzej S and Sullivan, David R and Lengyel, Imre and Stewart, Alan J and Arya, Swati and Ma, Ronald C and Galande, Sanjeev and Hardikar, Anandwardhan A and Joglekar, Mugdha V and Keech, Anthony C and Jenkins, Alicia J and Molloy, Mark P},
  title = {Optimised plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2023},
  doi = {10.1002/prca.202200106}
}
Kostenlos starten →